This press release contains statements which, to the extent that they are not recitations of historical fact may constitute forward-looking information under applicable Canadian securities legislation or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements or information may include financial and other projections as well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases are intended to identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.
Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the advancement of a new formulation of HspE7 that may produce better results in future clinical trials and our expectation that we will commence a Phase I bridging trial by mid-2007.
Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, events or developments, or industry results, to be
materially different from any future results, events or
developments expressed or implied by such forward-looking
statements or information. Such factors include, among others, our
need for capital, risks associated with requirements for approvals
by government agencies such as the F